Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2006 AND VI 24 AND IP 9
Results: 11
1
2
The Authors’ Reply.
- Published in:
- 2006
- By:
- Publication type:
- Letter
3
Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.
- Published in:
- 2006
- By:
- Publication type:
- commentary
4
Missing Data Imputation in Quality-of-Life Assessment: Imputation for WHOQOL-BREF.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 9, p. 917, doi. 10.2165/00019053-200624090-00008
- By:
- Publication type:
- Article
5
Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.
- Published in:
- 2006
- By:
- Publication type:
- journal article
6
Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 9, p. 891, doi. 10.2165/00019053-200624090-00006
- By:
- Publication type:
- Article
7
Cost-of-Illness Studies: A Review of Current Methods.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 9, p. 869, doi. 10.2165/00019053-200624090-00005
- By:
- Publication type:
- Article
8
Using discrete choice experiments within a cost-benefit analysis framework: some considerations.
- Published in:
- 2006
- By:
- Publication type:
- journal article
9
The value of thinly spread QALYs.
- Published in:
- 2006
- By:
- Publication type:
- journal article
10
Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance.
- Published in:
- 2006
- By:
- Publication type:
- journal article
11
US FDA guidance: apropos of PROs.
- Published in:
- 2006
- By:
- Publication type:
- Editorial